Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
Launched by ALCON RESEARCH · Dec 19, 2007
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female; minimum of 6 years of age and less than 12 years
- • 2 year history of seasonal allergic rhinitis
- Exclusion Criteria:
- • Concurrent disease that might interfere with the investigation or evaluation of te study medication
- • Confirmed diagnosis of chronic rhinosinusitis within the last year
- • Asthma, with the exception of mild intermittent asthma
- • Anatomical nasal deformity
- • Nasal obstruction
- • Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)
- • Chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids
- • Ocular disorder other that allergic conjunctivitis
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kenilworth, Illinois, United States
Patients applied
Trial Officials
Ed Tumaian
Study Director
ed.tumaian@alconlabs.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials